How GIP and GLP-1 Work Together for Metabolic Health

Every meal sets off two hormone signals from your gut, GIP and GLP-1, that prepare your body for the incoming sugar. Both tell the pancreas to release insulin only when blood sugar is actually rising, which is why they rarely push sugar too low on their own.¹ GLP-1 also slows the stomach and curbs appetite, while GIP adds effects on fat tissue and brain appetite centers.

The newest weight and diabetes drugs copy these signals, and the first to copy both at once, tirzepatide, has outperformed drugs that copy GLP-1 alone.²³ The two hormones are not simply doubling each other, though. They act on different tissues and the brain in different ways, and scientists are still debating parts of how GIP helps.

What GIP and GLP-1 Do After You Eat

GIP comes from cells in the upper intestine, and GLP-1 comes from cells further along. Both are released after a meal.⁴ The cells sense sugar arriving in the gut, partly through the same sugar-pumping channel that absorbs glucose.⁵ Hormones that boost insulin in response to eating are called incretins, which is the word your doctor may use for this whole drug family.

Both hormones rise within minutes of food reaching the intestine. Insulin output climbs ahead of the sugar peak, and the signals fade quickly once the meal is absorbed.

They fade fast because an enzyme in the intestinal blood vessels starts cutting both hormones the moment they are released.⁶ Natural GLP-1 lasts about 2 minutes in the blood, and GIP about 5 to 7 minutes.⁷ The liver and other tissues finish inactivating them, and the kidneys clear the leftovers.⁸

Natural GLP-1 would need constant infusion to work as a medicine. Injected drugs are instead engineered to resist this breakdown, so they linger for days, which is why semaglutide and tirzepatide are taken once a week. Older diabetes pills such as sitagliptin take the opposite approach and block the enzyme.⁹ They only raise your own hormones modestly, so their effect is smaller.

The pattern also differs. Your body releases these hormones in short bursts tied to meals, so the signal rises and falls several times a day. A weekly injection gives a steady level of drug in the blood. That steady exposure is part of why the drugs affect appetite across the whole day and not only at mealtimes.

How the Two Hormones Divide the Work

In the pancreas, both hormones act on insulin-making beta cells and flip the same internal switch, one that releases insulin only when glucose is high.¹⁰ In lab and animal work, both also help insulin cells survive and multiply.¹¹

Because of this glucose-dependence, these drugs on their own rarely cause dangerous lows. Low blood sugar shows up as shakiness, sweating, sudden hunger, a pounding heart or confusion. The risk is meaningfully higher if you also take insulin or a sulfonylurea, an older pill that forces insulin release regardless of sugar level. If you take either one, ask your prescriber before starting whether those doses should be lowered.

GIP has a role GLP-1 lacks with glucagon, the hormone that tells the liver to release stored sugar and so works against insulin. GIP prompts glucagon release when blood sugar is low or normal, but not when it is high.¹² That may make GIP a safety balance against low blood sugar. GLP-1 tends to hold glucagon down.

In the brain, receptors for both hormones sit in the hindbrain and hypothalamus, regions that control hunger and nausea.¹³ In mice, removing GIP receptors from the hypothalamus did not weaken the weight loss from combined treatment, which suggests the hindbrain may matter more.¹⁴ GIP signaling may also calm the brain’s nausea pathways, while GLP-1 slows stomach emptying.¹⁵

Fat tissue is where GIP is most distinctive. In lean people with insulin present, GIP quadrupled blood flow and fat clearance in belly fat tissue.¹⁶ That may help fat tissue safely store fat from the blood instead of letting it spill into the liver and muscle. When people were fasting, GIP had no such effect, suggesting it depends on insulin.¹⁷

Why Combining Them Took Scientists by Surprise

GIP had a poor reputation. In people with obesity and type 2 diabetes, GIP increased fat storage in belly fat, suggesting it could worsen obesity.¹⁸ But the belief that GIP drives weight gain came only from studies that switched GIP off, with no evidence that activating it adds weight.¹⁹

Both directions seem to work. Drugs that activate the GIP receptor (tirzepatide) and drugs that block it (maridebart cafraglutide, in trials) have both produced weight loss in people.²⁰ In mice, activating GIP works through its own brain neurons, while blocking it depends on GLP-1 signaling being present.²¹ The full explanation is still unsettled.

The two approaches may not contradict each other. Sustained activation can reduce a receptor’s responsiveness over time, so a constant drug signal may act differently from short natural bursts. That is one proposed explanation, and researchers have not shown it to be the answer.

Tirzepatide itself is lopsided. It acts on the GIP receptor as strongly as natural GIP but is about 20 times weaker than natural GLP-1 at its receptor.²² At the GLP-1 receptor it also favors the signaling path linked to insulin over one linked to receptor shutdown.²³ On paper that makes tirzepatide mostly a GIP drug with some GLP-1 action, though weekly dosing still delivers strong GLP-1 effects in practice. The tilt may help explain its results, but that is not proven.

Blood Sugar and Weight Results Compared With GLP-1 Alone

HbA1c on a lab report is your average blood sugar over about three months, and lowering it is the main diabetes goal. It is reported as a percentage, so a drop of 2 points could take someone from 9.5 to 7.5. In a head-to-head trial in type 2 diabetes, tirzepatide lowered HbA1c by 2.0 to 2.3 points depending on dose, versus 1.86 with semaglutide 1 mg.²⁴

That extra third to half a point can decide whether someone gets under a target, such as 7, that their doctor has set. Targets are personalized, and lower is not always better for every person.

Doses matter here. The 1.86 figure came from semaglutide 1 mg, which is not the top dose. Across trials, tirzepatide was similar to the higher 2 mg semaglutide dose, so the gap narrows when the comparison uses that dose.²⁵ Fair comparisons match doses and use the same kind of patients.

For weight in everyday care, people new to these drugs lost about 10.2 kg on tirzepatide versus 6.1 kg on semaglutide.²⁶ People switching from another such drug lost 7.9 kg versus 3.7 kg.²⁷ Dual drugs also improved cholesterol and fat levels more.²⁸ Choosing between them often comes down to cost and insurance coverage, along with how you responded to semaglutide before.

Not all of the weight lost is fat. About a quarter of weight lost on these drugs is lean tissue such as muscle.²⁹ Tirzepatide 15 mg and semaglutide 2.4 mg lost the most fat but also among the most lean mass.³⁰ Strength training and enough protein help protect muscle during treatment.

Effects on the Liver, Kidneys and Heart

Dual drugs cut liver fat about 2.9 times more than GLP-1 drugs alone in trials of fatty liver disease.³¹ Tirzepatide appears to reduce how much fat liver cells take up.³²

For the kidneys, people on dual therapy lost filtering function more slowly over a year, about 0.6 versus 1.5 units per year.³³ Protein leaking into urine dropped more, 27% versus 19%.³⁴ On your lab report, eGFR estimates how well your kidneys filter blood, and a higher number is better. Urine albumin, often reported as a ratio to creatinine, shows how much protein leaks into the urine, a sign of kidney strain.

In large trials tirzepatide lowered blood pressure along with weight and HbA1c.³⁵ Yet in a strain of severely hypertensive rats it raised blood pressure, so effects may depend on context.³⁶ Keep checking your blood pressure during treatment.

Side Effects and How to Ease Them

Nausea, vomiting, diarrhea and constipation are the most common side effects of both drug types.³⁷ Despite GIP’s possible nausea-calming effect, tirzepatide’s stomach side effects look much like GLP-1 drugs.³⁸ Belching rose with semaglutide but not tirzepatide, while both increased gas.³⁹ Tirzepatide may seem harsher partly because its top doses are relatively higher, so comparisons at matched doses are fairer.

Raising the dose slowly lets the body adapt over weeks to months.⁴⁰ Don’t skip dose steps, and ask about staying longer on a step if symptoms persist.

A few habits help day to day. Eat smaller portions and stop when you first feel full, since slowed stomach emptying makes overeating uncomfortable. Greasy, fried or very rich foods stay in the stomach longer and tend to worsen nausea. Sip fluids through the day, particularly if you are vomiting or have diarrhea, to avoid dehydration. Severe, persistent belly pain, sometimes with vomiting, should prompt a call to your doctor, since it can signal pancreatitis or gallbladder trouble.

What Happens When You Stop

Stopping these drugs reverses their effects, bringing back appetite and hormonal shifts toward weight gain.⁴¹ Hunger and thoughts about food often return within weeks as the drug level falls. In people with diabetes, blood sugar can rise again. The more weight you lost, the more there is to regain, and regain after stopping tirzepatide was greater than after semaglutide.⁴²

Plan with your doctor before stopping. Lower maintenance doses are sometimes used, muscle-building exercise supports metabolism, and regular weigh-ins catch regain early.

Triple Hormone Drugs on the Horizon

Tirzepatide was the first dual drug approved for both diabetes and obesity.⁴³ Drugs adding a third hormone, glucagon, are now in trials.⁴⁴ Early results show similar or better sugar control and weight loss.⁴⁵

Glucagon can raise energy use, so adding it may increase calories burned beyond the appetite effects. It may also help the liver burn fat, which could matter in fatty liver disease. Glucagon raises blood sugar by itself, but the GIP and GLP-1 actions are expected to offset that.

1
PubMed. GLP-1 and GIP receptor signaling in beta cells – A review of receptor interactions and co-stimulation ↩︎
2
PubMed. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes ↩︎
3
PubMed Central. Triple Agonism Based Therapies for Obesity ↩︎
4
PubMed Central. Molecular mechanisms underlying nutrient detection by incretin-secreting cells ↩︎
5
PubMed Central. Nutrition and L and K-enteroendocrine cells ↩︎
6
PubMed. Circulation and degradation of GIP and GLP-1 ↩︎
7
PubMed Central. Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment ↩︎
8
PubMed. Circulation and degradation of GIP and GLP-1 ↩︎
9
PubMed Central. Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment ↩︎
10
PubMed. GLP-1 and GIP receptor signaling in beta cells – A review of receptor interactions and co-stimulation ↩︎
11
PubMed. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation ↩︎
12
PubMed Central. The role of GIP in α-cells and glucagon secretion ↩︎
13
ADA Meeting News. New data underscores importance of GIP signaling in the brain to regulating food intake, energy balance ↩︎
14
ADA Meeting News. New data underscores importance of GIP signaling in the brain to regulating food intake, energy balance ↩︎
15
PubMed Central. Adverse Events Associated with Incretin-Based Therapies: A Narrative Review on Mechanisms, Clinical Management, and Risk Mitigation ↩︎
16
PubMed Central. The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue ↩︎
17
PubMed Central. The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue ↩︎
18
PubMed. Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response ↩︎
19
PubMed Central. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms ↩︎
20
PubMed Central. A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice ↩︎
21
PubMed Central. GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice ↩︎
22
PubMed Central. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist ↩︎
23
PubMed Central. Structural determinants of dual incretin receptor agonism by tirzepatide ↩︎
24
PubMed. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes ↩︎
25
PubMed Central. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials ↩︎
26
PubMed Central. Real-World Effectiveness of Tirzepatide versus Semaglutide on HbA1c and Weight in Patients with Type 2 Diabetes ↩︎
27
PubMed Central. Real-World Effectiveness of Tirzepatide versus Semaglutide on HbA1c and Weight in Patients with Type 2 Diabetes ↩︎
28
PubMed Central. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists ↩︎
29
PubMed. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis ↩︎
30
PubMed. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis ↩︎
31
PubMed Central. Efficacy of GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists in managing MALFD: a meta-analysis of randomized controlled trials ↩︎
32
PubMed Central. Tirzepatide, a dual GIP/GLP-1 receptor agonist, alleviates metabolic dysfunction-associated steatotic liver disease by reducing the expression of CD36 and OBP2A ↩︎
33
Imperium Académico Multidisciplinary Journal. Resultados renales de GLP-1 y agonistas duales de GIP/GLP-1: una nueva frontera en nefrología ↩︎
34
Imperium Académico Multidisciplinary Journal. Resultados renales de GLP-1 y agonistas duales de GIP/GLP-1: una nueva frontera en nefrología ↩︎
35
PubMed. Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus and obesity ↩︎
36
PubMed. Effects of tirzepatide, a dual GIP and GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats ↩︎
37
PubMed Central. Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations ↩︎
38
PubMed Central. Adverse Events Associated with Incretin-Based Therapies: A Narrative Review on Mechanisms, Clinical Management, and Risk Mitigation ↩︎
39
PubMed Central. Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations ↩︎
40
PubMed Central. Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis ↩︎
41
European Journal of Medical Research. Challenge following discontinuation of incretin-based anti-obesity drugs: weight relapse and prevention strategies ↩︎
42
PubMed Central. Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysis ↩︎
43
PubMed Central. Triple Agonism Based Therapies for Obesity ↩︎
44
PubMed Central. Triple Agonism Based Therapies for Obesity ↩︎
45
PubMed. Next generation dual GLP-1/GIP, GLP-1/glucagon, and triple GLP-1/GIP/glucagon agonists: a literature review ↩︎